MedTrace Logo

Chemoradiotherapy in Unresectable Esophageal Cancer

NCT04278287 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2024-12-13

No results posted yet for this study

Summary

This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.

Conditions

  • Esophageal Cancer
  • Chemoradiotherapy
  • Albumin-bound Paxlitaxel
  • Unresectable Malignant Neoplasm

Interventions

RADIATION

Radiotherapy

59.92Gy and 2.14Gy in 28 fractions to PGTV and 50.4Gy and 1.8Gy in 28 fractions 5 days every week in 5.5 weeks.

DRUG

Albumin-Bound Paclitaxel

100mg/d weekly,repeatedly on the first day,by intravenous infusion in 5-6 weeks.

DRUG

Cisplatin

25mg/m2 weekly,by intravenous infusion in 5-6 weeks.

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Xin Wang, MD · Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04278287 on ClinicalTrials.gov